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Antifungal activityAbstract A series of some novel sulphur and nitrogen containing ferrocenyl linked heterocyclic
compounds were synthesized by multistep reactions and evaluated for in vitro antimicrobial activity
against 15 ATCC strains out of which 8 were bacterial (Pseudomonas aeruginosa, Streptococcus
bovis, Enterococcus faecalis, Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae,
Methicillin-resistant Staphylococcus aureus and Streptococcus mutans) and 7 were fungal
(Candida albicans, Candida dubliniensis, Candida glabrata, Candida parapsilosis, Candida tropicalis,
Candida kefyr and Candida krusei) strains. The results clearly depict that the compounds (1–12) gave
an average antimicrobial activity against the tested strains with an exception of compound 12 which
stood out in terms of its activity against the tested organisms. All these compounds gave a range of
MIC value between 32–64 lg/ml against S. bovis, E. coli and C. tropicalis except compound 12
which gave a MIC of 16 lg/ml against each of them. The MIC values of all these compounds
against bioﬁlm forming P. aeruginosa and S. mutans were 64–256 lg/ml and 64–128 lg/ml
respectively which is apparently high, concluding that these compounds hold immense potential
to be employed as a two in one formulation of antibacterial as well as antifungal agents.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the past few decades, the incidence of microbial infection
has increased on frightening level over the world as a result
of antimicrobial resistance (Ghannoum and Rice, 1999; Fluit
et al., 2001; Canuto and Rodero, 2002; Pfaller and Diekema,
2007; Mukherjee et al., 2005; Shapiro et al., 2011). Microbialometal-
2 H. Parveen et al.infections are a growing problem in contemporary medicine
and the use of antibiotics is common across the world.
Consequently, there is an urgent need to widen antimicrobial
agents, which have a broad spectrum of activity against the
resistant microorganisms. The current literature is enriched
with progressive ﬁndings about the synthesis and pharmaco-
logical action of fused heterocycles such as pyrazolines and
related heterocyclic compounds (Yusuf and Jain, 2014;
Kathiravan et al., 2012).
On the other hand, ferrocene and its derivatives, since
their discovery have been attracting much attention due to
their wide range of applications in catalysis, material sciences
(Togni and Hayashi, 1995), biological studies and even in
therapy (Jaouen et al., 2006; Lang and Heinze, 2013;
Stepnicka, 2008; Scarcia et al., 1988; Hill et al., 1989;
Neuse and Kanzawa 1990; Motohashi et al., 1990; Houlton
et al., 1991; Top et al., 2001; Klimova et al., 2001; Ma
et al., 2001; Delhaes et al., 2001; Weber et al., 2004;
Jaouen et al., 2004; Bincoletto et al., 2005; Hillard et al.,
2006). Ferroquine, the ferrocenyl derivative of antimalarial
drug chloroquine, is currently at the phase II clinical trial
stage as the best promise against the chloroquine-resistant
strains of Plasmodium falciparum (Biot et al., 2005; Dive
and Biot, 2008; Biot and Dive, 2010; Supan et al., 2012).
Many ferrocenyl compounds also display interesting
cytotoxic, anti-tumor, anticancer, antimalarial, antifungal
and DNA-cleaving activity (Kealy and Pauson, 1951; Kelly
et al., 2007; Fouda et al., 2007). Recently, some new
ferrocenyl-substituted heterocyclic compounds have been
reported as potential pharmaceuticals (Huang et al., 2014;
Arancibia et al., 2014; Harry et al., 2014; Yu et al., 2007;
Zora and Go¨rmen, 2007; Zora and Veliog˘lu, 2008; Fabian
et al., 2007; Mochida et al., 2007; Maity et al., 2008).
Moreover, the stability and nontoxicity of the ferrocenyl
moiety is of particular interest rendering such drugs compat-
ible with other treatment (Biot et al., 2000). In this sense, the
integration of one or more ferrocene units into a heterocyclic
molecule has long been recognized as an attractive way to
endow a novel molecule functionality (Sun et al., 2002;
Haung and Wang, 2001). Recent publications also
support that combination of pharmacologically active N-
heterocycles among them pyrazolines and pyrazoles with
ferrocene moiety results in favourable change of biological
properties, often associated with decreased toxicity
(Delhaes et al., 2001; Va´zquez Lo´pez et al., 2004; Fang
et al., 2003). Moreover, thiazoles are found in many
biologically active compounds, including natural products
and pharmaceutical agents (Kashyap et al., 2012; Eicher
and Hauptmann, 2003; Siddiqui et al., 2011) and it is well
documented that the combination of two or more types of
heterocycles into one molecule could afford a novel entity
with increased bioactivities (Zhou and Wang, 2012; Wang
and Zhou, 2011).
In view of these observations and as a part of our ongo-
ing search devoted to the synthesis of biologically active
heterocycles (Iqbal et al., 2009; Parveen et al., 2010, 2011)
we report herein some novel 5-ferrocenyl-3-substituted aryl-
4,5-dihydro-1H-pyrazol-1-carbothioamides (1–6) and their
cyclized products 2-(5-ferrocenyl-3-aryl-4,5-dihydro-1H-pyra
zol-1-yl)-4-(4-substituted-aryl) thiazoles (7–12), as useful
leads towards the development of potent antimicrobial
agents.Please cite this article in press as: Parveen, H. et al., Synthesis, characterization and bi
lic heterocycles. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.ar2. Results and discussion
2.1. Synthesis
The aforementioned compounds were prepared according to
the synthetic sequences illustrated in Scheme 1. The ferrocenyl
chalcones (a–f), were prepared by a classic Claisen–Schmidt
condensation of substituted acetophenones/1-phenyl butane-
1-one/2-acetyl ferrocene with ferrocene carboxaldehyde in
the presence of KOH and absolute ethanol. The cyclization
of ferrocenyl chalcones (a–f), with thiosemicarbazide and
sodium hydroxide in the presence of absolute ethanol yielded
their corresponding pyrazoline analogues 5-ferrocenyl-3-aryl-
4,5-dihydro-1H-pyrazole-1-carbothioamides (1–6), which were
further cyclized with 2-bromo-40ﬂuro acetophenone to yield
their corresponding 2-(5-ferrocenyl-3-aryl-4,5-dihydro-1H-pyr
azol-1-yl)-4-(4-substituted-phenyl)thiazoles (7–12). According
to the mechanism, the formation of pyrazoline analogues is
favoured via thiosemicarbazone formation, which undergoes
cyclization under basic condition to form desired pyrazoline
ring in all the compounds.
All the synthesized compounds were characterized by spec-
troscopic methods such as IR, 1H NMR 13C NMR and Mass
and the purity of compounds was conﬁrmed by elemental anal-
ysis and melting points. All compounds showed sharp melting
points and the elemental analysis was found in accordance
with ±0.3%. The analytical data are presented in the experi-
mental section.
In the IR spectra of ferrocenyl chalcones (a–f), the appear-
ance of characteristic bands at 1642–1655 cm1 and 1568–
1580 cm1 due to a, b unsaturated carbonyl group and
C‚C, respectively, suggested the condensation of substituted
ketones/1-phenyl butane-1-one/2-acetyl ferrocene with fer-
rocene carboxaldehyde. The structures of all these compounds
were further conﬁrmed by 1H NMR spectra. The appearance
of doublets in the region of d 6.75–7.35 ppm for Ha and
6.82–7.71 ppm for Hb with coupling constant (J) in the range
of 15.2–16 Hz showed that they are transisomers. The rest of
protons appeared in the expected region and their values are
shown in the data given in experimental section. Additional
support for the structures of the compounds (a–f), was
obtained from 13C NMR. A characteristic signal for the
ferrocenyl chalcones (C‚O) appeared in the range of d
189.81–192.00 ppm. The signals at d 120.23–122.43 and
142.46–146.82 ppm conﬁrmed the presence of a, b unsaturated
keto function in all compounds (a–f).
Selected diagnostic bands of the IR spectra of pyrazoline
analogues (1–6) of ferrocenyl chalcones (a–f) showed useful
information about the structures of the compounds. All the
compounds showed intense bands in the region 1032–
1078 cm1 due to m (C‚S) stretch of the thiocarboxamide
group. The IR spectra of all the compounds showed m
(C‚N) stretch at 1524–1587 cm1 because of the ring closure.
In addition, the absorption bands at 1125–1215 cm1 were
attributed to the m (CAN) stretch vibrations, which also con-
ﬁrmed the formation of the desired pyrazoline ring in all the
compounds. The structures of the pyrazoline analogues were
further supported by their 1H NMR spectra which provided
diagnostic tools for the positional elucidation of the protons.
Assignments of the signals are based on the chemical shifts
and intensity patterns. The pyrazoline protons Ha and Hbological evaluation of some novel nitrogen and sulphur containing organometal-
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Scheme 1 General synthesis of 5-ferrocenyl-3-substituted aryl-4,5-dihydro-1H-pyrazol-1-carbothioamides (1–6) and their cyclized
derivatives (7–12).
Synthesis, characterization and biological evaluation organometallic heterocycles 3(Fig. 1) are geminal protons at C-4 carbon and appeared in the
region of 3.35–3.36 and 3.50–3.83 ppm as doublet of doublets
in all the compounds. The CAH proton (Hx) of the pyrazoline
ring also appeared as doublet of doublets in the region of 6.30–
5.91 ppm due to vicinal coupling with two nonequivalent ger-
minal protons of C-4 carbon. The protons belonging to the
aromatic ring and ferrocenyl group were observed within the
expected chemical shift region along with the integral values
and are shown in the data given in the experimental section.
The structures of the pyrazoline derivatives (7–12) were also
conﬁrmed by spectral studies. The IR spectra of all these com-
pounds showed m (C‚N) stretch at 1582–1598 cm1 which
suggest the formation of thiazole ring. The 1H NMR spectra
of these compounds also support the proposed structures of
these compounds. The H-5 proton of thiazole ring was
observed as a singlet between 6.68–6.82 ppm, conﬁrming the
formation of thiazole ring in all the compounds. In addition,
four protons in monosubstituted Cp of ferrocene moiety of
the compounds (7–12) appeared as three singlet peaks in the
region of 4.68–4.82, 4.64–4.69 and 4.59–4.61 ppm and ﬁve pro-
tons of unsubstituted Cp also appeared as a singlet in the
region of 4.24–4.27 ppm. All the other aromatic and aliphatic
protons were observed with expected chemical shift and inte-
gral values and are shown in the data given in the experimental
section and the structures of all newly synthesized compoundsPlease cite this article in press as: Parveen, H. et al., Synthesis, characterization and bi
lic heterocycles. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.ar(1–6) and (7–12) were further conﬁrmed by mass spectrometry.
All compounds showed a particular molecular ion peak which
was in conformity with the respective molecular formula of
compounds.2.2. In vitro antimicrobial study
All the newly synthesized compounds (1–6) and (7–12) were
screened for antimicrobial activity against 15 ATCC strains
out of which 8 were bacterial (P. aeruginosa, S. bovis,
E. faecalis, K. pneumonia, E. coli, E. cloacae, MRSA and S.
mutans) and 7 were fungal (C. albicans, C. dubliniensis, C.
glabrata, C. parapsilosis, C. tropicalis, C. kefyr and C. krusei)
strains by broth microdilution method (Hasan et al., 2013,
2012). Four Gram-positive bacteria (Streptococcus bovis,
Enterococcus, faecalis, Methicillin-resistant Staphylococcus
aureus and Streptococcus mutans) and Four Gram-negative
bacteria (Pseudomonas aeruginosa, Klebsiella pneumoniae,
Escherichia coli, and Enterobacter cloacae) were used for
antibacterial assay. The antibacterial effect was compared with
the most widely used antibiotic Amoxicillin. This antibiotic is
used for the treatment of a number of bacterial infections
including both Gram-positive and Gram-negative bacteria.
In our experiments it gave a minimum inhibitoryological evaluation of some novel nitrogen and sulphur containing organometal-
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Figure 1 Novel nitrogen and sulphur containing organometallic heterocycles (1–12).
Table 1 MIC (lg/ml) value of synthesized compounds (1–12) on the tested ATCC strains using broth microdilution method.
Compounds Bacterial strains Fungal strains
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1 256 64 32 128 64 128 256 128 128 256 128 128 64 128 128
2 128 32 32 128 32 128 128 64 128 256 64 64 32 64 128
3 128 64 32 64 32 128 128 128 128 256 64 128 64 128 128
4 128 32 32 64 32 64 64 128 128 256 64 64 32 256 128
5 128 64 32 64 64 64 64 128 128 128 64 128 64 128 128
6 128 64 64 128 32 64 128 128 128 128 64 64 32 128 128
7 128 64 32 128 32 128 64 128 128 128 64 128 32 128 128
8 128 32 32 128 32 128 128 256 256 256 64 64 32 128 128
9 256 64 64 128 32 64 128 256 128 256 64 128 32 128 128
10 128 32 32 64 64 64 64 128 256 256 64 64 64 64 128
11 128 32 32 64 32 128 128 128 128 256 64 128 32 128 128
12 64 16 16 64 16 32 32 64 64 64 32 32 16 64 64
Amoxycillin 64 8 8 16 8 16 16 16 – – – – – – –
Fluconazole – – – – – – – 64 64 64 64 64 64 64
4 H. Parveen et al.concentration (MIC) of 8–64 lg/mL against the tested strains.
The results clearly depict that the compounds (1–12) substi-
tuted at position 4 in the benzene ring, in pyrazoline moiety
with ferrocenyl, phenyl ethyl, phenyl, hydroxy and bromo
group, gave an average antimicrobial activity against the testedPlease cite this article in press as: Parveen, H. et al., Synthesis, characterization and bi
lic heterocycles. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arstrains with an exception of compound 12 in the benzene ring,
in pyrazoline moiety which fell into a close bracket of activity
to Amoxicillin, that is, the activity of compound 12 was
comparable to that of Amoxicillin. The MIC values of rest
of the compounds against bioﬁlm forming P. aeruginosa andological evaluation of some novel nitrogen and sulphur containing organometal-
abjc.2015.05.002
Table 2 Strains used to study antibacterial/antifungal activity
of synthesized compounds.
Code Names of organisms (ATCC)
1 Pseudomonas aeruginosa
2 Streptococcus bovis
3 Enterococcus faecalis
4 Klebsiella pneumoniae
5 Escherichia coli
6 Enterobacter cloacae
7 Methicillin-resistant Staphylococcus aureus [MRSA]
8 Streptococcus mutans
9 Candida albicans
10 Candida dubliniensis
11 Candida glabrata
12 Candida parapsilosis
13 Candida tropicalis
14 Candida kefyr
15 Candida krusei
Synthesis, characterization and biological evaluation organometallic heterocycles 5S. mutans were 64–256 lg/ml and 64–128 lg/ml respectively
which is apparently high.
All these compounds gave a range of MIC value between
32–64 lg/ml against S. bovis, E. coli and C. tropicalis except
compound 12 which gave a MIC of 16 lg/ml against each of
them. The results of antibacterial activity are summarized in
Table 1.
2.3. In vitro antifungal activity
The antifungal activity of all compounds was screened against
7 fungal strains (Candida albicans, Candida dubliniensis,
Candida glabrata, Candida parapsilosis, Candida tropicalis,
Candida kefyr and Candida krusei). The effect was compared
with the most widely used antifungal agent Fluconazole. It is
a well-established ﬁrst-line management option for the treat-
ment of Candida infections. In our experiments it gave a min-
imum inhibitory concentration (MIC) of 64 lg/mL against all
the tested strains. The results of antifungal activity indicated
that out of all the tested compounds, compound 12, having
nitro group at position 4 in the benzene ring, in pyrazoline
moiety showed comparable or even better antifungal activity
than Fluconazole against C. glabrata (32 lg/mL), C. parapsilo-
sis (32 lg/mL), C. tropicalis (16 lg/mL). The results of antifun-
gal activity are summarized in Table 1.
3. Conclusion
Some novel sulphur and nitrogen containing ferrocenyl linked
heterocyclic compounds were synthesized and well character-
ized by spectroscopic methods such as IR, 1H NMR 13C
NMR, Mass and elemental analyses. All the newly synthesized
compounds (1–12) were screened for in vitro antimicrobial
activity by broth microdilution method against 15 ATCC
strains out of which 8 were bacterial (P. aeruginosa, S. bovis,
E. faecalis, K. pneumonia, E. coli, E. cloacae, MRSA and
S. mutans) and 7 were fungal (C. albicans, C. dubliniensis,
C. glabrata, C. parapsilosis, C. tropicalis, C. kefyr and C. krusei)
strains. The results of antimicrobial activity conclude that
these compounds hold immense potential to be employed as
a two in one formulation of antibacterial as well as antifungalPlease cite this article in press as: Parveen, H. et al., Synthesis, characterization and bi
lic heterocycles. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.aragents. Also, being novel they can be a solution to the increas-
ing resistance that has posed a major problem globally.4. Experimental protocol
All the chemicals were purchased from Aldrich Chemical
Company (USA). Precoated aluminium sheets (silica gel 60
F254, Merck Germany) were used for thin-layer chromatogra-
phy (TLC) and spots were visualized under UV light. Melting
points were determined on Stuart SMP10 melting point appa-
ratus and are uncorrected. IR spectra were recorded on
Perkin–Elmer model 1600 FT-IR RX1 spectrophotometer as
KBr discs. 1H NMR and 13C NMR spectra were recorded
on Bruker DPX-600 FT NMR spectrometer using CDCl3 as
solvent with TMS as internal standard. Splitting patterns are
designated as follows: s, singlet; d, doublet; dd, double dou-
blet; m, multiplet. Chemical shift values are given in ppm.
Elemental analyses were performed on a 2400 Perkin Elmer
Series II analyser. ESI-MS was recorded on a MICROMASS
QUATTRO II triple quadrupole mass spectrometer.
4.1. General procedure for the preparation of ferrocenyl
chalcones (a–f)
The substituted aromatic ketone (3 mmol) and KOH (0.2 g)
was dissolved in ethanol (5 mL) in a round bottomed ﬂask
and stirred at room temperature (25 C) for 10 min. An
ethanolic solution of the ferrocene carboxaldehyde (3 mmol,
5 mL) was added dropwise to the reaction mixture and stirred
at room temperature. The progress of the reaction was moni-
tored by TLC on silica gel sheets. The reaction was stopped
by neutralizing the stirred solution with 2 M HCl. In most
cases the product was obtained as a dark red precipitate after
neutralization. It was then removed by ﬁltration, and washed
with water. In the absence of a precipitate on neutralization,
the solution was extracted with ethyl acetate (20 mLx3). The
organic layer was dried over anhydrous sodium sulphate and
removed by evaporation under reduced pressure to give a liq-
uid residue. The latter was passed through a column of silica
gel (230–400 mesh) and eluted with THF–hexane (1:4) to yield
pure compound.
4.1.1. 1,3-Diferrocenyl-2-propen-1-one (a)
Yield 92%; m.p. 205 C; deep red solid; Anal. calc. for
C23H20Fe2O: C 65.11, H 4.75%. Found: C, 65.10, H 4.72%
IR mmax (cm
1): 3054 (ArAH), 2930 (CAH), 1652 (C‚O),
1573 (C‚C); 1H NMR (CDCl3) d (ppm): 6.82 (d, 1H,
J= 16 Hz, Hb), 6.75 (d, 1H, J= 16 Hz, Ha), 4.61 (s, 2H, fer-
rocene), 4.46 (s, 2H, ferrocene), 4.58 (s, 2H, ferrocene), 4.55 (s,
2H, ferrocene), 4.19 (s, 5H, ferrocene), 4.16 (s, 5H, ferrocene);
13C NMR (CDCl3) d (ppm): 192.00 (C‚O), 142.46 (C-b),
79.46, 78.52 (2 ipso-C5H4), 71.95, 71.40, (2 meta-C5H4),
70.86, 70.48, (2 ortho-C5H4), 69.81,70.05 (2 C5H5), 120.23
(C-a); ESI-MS m/z: [M++1] 425.00.
4.1.2. 5-Ferrocenyl-1-(phenyl)-pent-4-en-1-one (b)
Yield 75%; reddish gummy product; Anal. calc. for
C21H20FeO: C 73.27, H 5.86%. Found: C 73.29; H 5.84%.
IR mmax (cm
1): 3035 (ArAH), 2936 (CAH), 1642 (C‚O),
1578 (C‚C); 1H NMR (CDCl3) d (ppm): 7.88–7.63 (m, 2H,ological evaluation of some novel nitrogen and sulphur containing organometal-
abjc.2015.05.002
6 H. Parveen et al.ArAH), 7.69 (d, 1H, J= 15.2 Hz, Hb), 7.56–7.21 (m, 3H,
ArAH), 7.33 (d, 1H, J= 15.2 Hz, Ha), 4.61 (s, 2H, ferrocene),
4.46 (s, 2H, ferrocene), 4.17(s, 5H, ferrocene), 2.98–2.86 (m,
2H, CH2), 2.85–2.64 (m, 2H, CH2);
13C NMR (CDCl3) d
(ppm): 189.81 (C‚O), 146.45 (C-b), (138.67, 133.77, 128.59,
128.45, aromatic), 121.61 (C-a), 21.59 (CH3), 77.5 (ipso-
C5H4), 69.8, 69.5 (meta-C5H4), 69.4, 69.0 (C5H5), 67.4, 66.3
(ortho-C5H4); ESI-MS m/z: [M
++1] 345.22.
4.1.3. 3-Ferrocenyl-1-phenyl-2-propen-1-one (c)
Yield 90%; m.p. 144 C; deep red solid; Anal. calc. for
C19H16FeO: C 72.17, H 5.10%. Found: C 72.12; H 5.06%.
IR mmax (cm
1): 3031 (ArAH), 2935 (CAH), 1655 (C‚O),
1568 (C‚C); 1H NMR (CDCl3) d (ppm): 7.92–7.88 (m, 2H,
ArAH), 7.70 (d, 1H, J= 15.2 Hz, Hb), 7.57–7.15 (m, 3H,
ArAH), 7.33 (d, 1H, J= 15.2 Hz, Ha), 4.60 (s, 2H, ferrocene),
4.48 (s, 2H, ferrocene), 4.18 (s, 5H, ferrocene); 13C NMR
(CDCl3) d (ppm): 189.88 (C‚O), 146.82 (C-b), (138.63,
132.44, 128.59, 128.40, aromatic), 122.17 (C-a), 77.5 (ipso-
C5H4), 69.9, 69.6 (meta-C5H4), 69.5, 69.2 (C5H5), 67.5, 66.4
(ortho-C5H4); ESI-MS m/z: [M
++1] 317.17.
4.1.4. 3-Ferrocenyl-1-(4-hydroxyphenyl)-2-propen-1-one (d)
Yield 95%; m.p: 225 C reddish brown solid; Anal. calc. for
C19H16FeO2: C 68.70, H 4.85. Found: C 67.05, H 5.74% IR m
max cm1: 3041 (ArAH), 2933 (CAH), 1645 (C‚O), 1571
(C‚C); 1H NMR (CDCl3) d (ppm): 7.83–7.76 (m, 2H,
ArAH), 7.71 (d, 1H, J= 15.6 Hz, Hb), 7.59–7.42 (m, 2H,
ArAH), 7.34 (d, 1H, J= 15.6 Hz, Ha), 4.92 (s, 2H, fer-
rocene), 4.58 (s, 2H, ferrocene), 4.24 (s, 5H, Ferrocene),
4.22 (s, 1H, OH); 13C NMR (CDCl3) d (ppm): 191.16
(C‚O), 144.64 (C-b), (138.61, 132.71, 130.04, 128.52,
Aromatic), 122.24 (C-a), 77.2 (ipso-C5H4), 69.8, 69.5 (meta-
C5H4), 69.2, 69.0 (C5H5), 67.8, 66.9 (ortho-C5H4); ESI-MS
m/z: [M++1] 333.17.
4.1.5. 3-Ferrocenyl-1-(4-bromophenyl)-2-propen-1-one (e)
Yield 95%; m.p: 168 C red solid; Anal. calc. for
C19H15BrFeO: C 57.76, H 3.83%. Found: C, 57.86, H 3.94%
IR mmax (cm
1): 3051 (ArAH), 2930 (CAH), 1650 (C‚O),
1580 (C‚C); 1H NMR (CDCl3) d (ppm): 7.81–7.67 (m, 4H,
ArAH), 7.61 (d, 1H, J= 16 Hz, Hb), 7.32 (d, 1H,
J= 16 Hz, Ha), 4.96 (s, 2H, ferrocene), 4.61 (s, 2H, ferrocene),
4.26 (s, 5H, ferrocene); 13C NMR (CDCl3) d (ppm): 191.43
(C‚O), 143.41 (C-b), (136.07, 134.70, 130.02, 128.51,
Aromatic), 121.42 (C-a), 77.2 (ipso-C5H4), 69.9, 69.7 (meta-
C5H4), 69.5, 69.2 (C5H5), 67.6, 66.4 (ortho-C5H4); ESI-MS
m/z: [M++1] 396.07.
4.1.6. 3-Ferrocenyl-1-(4-nitrophenyl)-2-propen-1-one (f)
Yield 90%; m.p: 214 C; deep red solid; Anal. calc. for
C19H15FeNO3: C 63.18, H 4.19, N 3.85%. Found: C 63.15,
H 4.14 N 3.82%. IR mmax (cm
1): 3067 (ArAH), 2938
(CAH), 1647 (C‚O), 1575 (C‚C); 1H NMR (CDCl3) d
(ppm) 8.12–8.06 (m, 2H, ArAH), 7.67 (d, 1H, J= 15.6 Hz,
Hb), 7.64–7.22 (m, 2H, ArAH), 7.35 (d, 1H, J= 15.6 Hz,
Ha), 4.61 (s, 2H, ferrocene), 4.48 (s, 2H, ferrocene), 4.19 (s,
5H, ferrocene); 13C NMR (CDCl3) d (ppm): 189.88 (C‚O),
146.47 (C-b), (138.60, 132.72, 128.53,127.54, aromatic),
122.43 (C-a). 77.7 (ipso-C5H4), 69.8, 69.7 (meta-C5H4), 69.5,Please cite this article in press as: Parveen, H. et al., Synthesis, characterization and bi
lic heterocycles. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.ar69.3 (C5H5), 67.4, 66.2 (ortho-C5H4); ESI-MS m/z: [M
++1]
362.17.
4.2. General procedure for the synthesis of 5-ferrocenyl-3-
substituted aryl-4,5-dihydro-1H-pyrazol-1-carbothioamides (1–6)
Thiosemicarbazide (12.6 mmol) was dissolved in absolute
ethanol (50 mL) by reﬂuxing under nitrogen. Then a solution
of corresponding chalcone (a–f) (6.3 mmol), and NaOH
(15.8 mmol) in absolute ethanol was added and the reaction
mixture was reﬂuxed for 6 h. The progress of the reaction
was monitored by TLC on silica gel sheets. After completion
of the reaction, reaction mixture was cooled to room
temperature, then water (25 ml) was added to the reaction
mixture and the solid obtained, was ﬁltered, dried and recrys-
tallized by appropriate solvent to yield corresponding pyrazo-
lines (1–6).
4.2.1. 3,5-Diferrocenyl-4,5-dihydropyrazole-1-carbothioamide
(1)
Yield 70%; m.p: 214 C; reddish brown solid. Anal. calc. for.
C24H23Fe2N3S: C (57.97%) H (4.66%) Fe (22.46%) N
(8.45%) S (6.45%) IR mmax (cm
1): 3370, 3166 (NAH), 1587
(C‚N), 1258 (CAN), 1054 (C‚S); 1H NMR (CDCl3) d
(ppm) 6.85 (s, 2H, -NH2), 6.32 (dd, 1H, Hx, Jax = 10.9,
Jbx = 10.2 Hz, pyrazoline), 4.85 (s, 2H, ferrocene), 4.79 (s,
2H, ferrocene), 4.56 (s, 2H, ferrocene), 4.46 (s, 2H, ferrocene),
4.19 (s, 5H, ferrocene), 4.16 (s, 5H, ferrocene), 3.50
(dd, 1H, Hb, Jab = 17.4, Jbx = 10.2 Hz, pyrazoline), 3.47
(dd, 1H, Ha, Jab = 17.4, Jax = 3.2 Hz pyrazoline);
13C NMR
(CDCl3) d (ppm): 177.6 (C‚S) pyrazoline), 159.5, (C‚N),
58.7, (C-5, pyrazoline), 42.0 (C-4, pyrazoline) 72.5,
71.7 (2 · ipso-C5H4), 71.3, 71.1 (2 ·meta-C5H4), 70.7,
70.1 (2 · C5H5), 67.8, 65.8 (2 · ortho C5H4); ESI-MS m/z:
[M++1] 498.21.
4.2.2. 5-Ferrocenyl-3-(2-phenylethyl)-4,5-dihydropyrazole-1-
carbothioamide (2)
Yield 68%; brown gummy product. Anal. calc. for.
C22H23FeN3S: C (63.31%) H (5.55%) Fe (13.38%) N
(10.07%) S (7.68%); IR mmax (cm
1): 3354, 3174 (NAH),
1582 (C‚N), 1262 (CAN), 1078 (C‚S); 1H NMR (CDCl3) d
(ppm) 7.32–7.45 (m, 5H, ArAH), 6.81 (s, 2H, -NH2), 6.09
(dd, 1H, Hx, Jax = 10.5, Jbx = 11.2 Hz, pyrazoline), 4.51 (s,
1H, ferrocene), 4.47 (s, 1H, ferrocene), 4.38 (s, 2H, ferrocene),
4.27 (s, 5H, ferrocene), 3.83 (dd, 1H, Hb, Jab = 16.8,
Jbx = 11.2 Hz, pyrazoline), 3.35 (dd, 1H, Ha, Jab = 16.8,
Jax = 4.2 Hz, pyrazoline), 3.21–2.98 (m, 2H, CH2AAr), 2.92–
2.8 (m, 2H, CH2);
13C NMR (CDCl3) d (ppm): 174.9 (C‚S)
pyrazoline), 160.3, (C‚N), 60.9, (C-5, pyrazoline), 44.0 (C-4,
pyrazoline), 145.1–125.1 (ArAC), 71.5 (ipso-C5H4), 69.9, 69.7
(meta-C5H4), 68.8, 68.6 (C5H5), 67.9, 67.7 (ortho C5H4), 29.4,
27.5 (2 · CH2), ESI-MS m/z: [M++1] 418.34.
4.2.3. 5-Ferrocenyl-3-phenyl-4,5-dihydropyrazole-1-
carbothioamide (3)
Yield 62% m.p: 210 C; orange solid. Anal. calc. for
C20H19FeN3S: C (61.70%) H (4.92%) Fe (14.35%) N
(10.79%) S (8.24%); IR mmax (cm
1): 3355, 3190 (NAH),
1550 (C‚N), 1210 (CAN), 1034 (C‚S); 1H NMR (CDCl3)ological evaluation of some novel nitrogen and sulphur containing organometal-
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Jax = 11.1, Jbx = 10.2 Hz, pyrazoline), 6.86 (s, 2H, -NH2),
4.61 (s,1H, ferrocene), 4.52 (s, 1H, ferrocene), 4.44 (s, 2H, fer-
rocene), 4.14 (s, 5H, ferrocene) 3.68 (dd, 1H, Hb Jab = 16.8,
Jbx = 10.2, pyrazoline), 3.59 (dd, 1H, Ha, Jab = 16.8,
Jax = 3.2 pyrazoline);
13C NMR (CDCl3) d (ppm): 176.47
(C‚S), 156.8 (C‚N), 59.4, (C-5, pyrazoline) 41.9 (C-4, pyra-
zoline), 141.61–125.13 (ArAC), 76.2 (ipso-C5H4), 69.9, 69.8
(meta-C5H4), 69.3, 69.0 (C5H5), 67.2, 66.6 (ortho-C5H4),
ESI-MS m/z: [M++1] 390.29.
4.2.4. 5-Ferrocenyl-3-(4-hydroxyphenyl)-4,5-dihydropyrazole-
1-carbothioamide (4)
Yield 74%; m.p: 209 C; orange solid. Anal. calc. for
C20H19FeN3OS: C (59.27%) H (4.73%) Fe (13.78%) N
(10.37%) O (3.95%) S (7.91%); IR mmax (cm
1): 3257, 3165
(NAH), 1562 (C‚N), 1195 (CAN), 1044 (C‚S); 1H NMR
(CDCl3) d (ppm) 7.75 (d, 2H, J= 7.8 Hz, ArAH), 7.20 (d,
2H, J= 7.8 Hz, ArAH), 6.88 (s, 2H, ANH2), 6.33 (dd, 1H,
Hx, Jax = 10.9, Jbx = 10.2 Hz, pyrazoline), 4.72 (s, 1H,
OH), 4.65 (s, 1H, ferrocene), 4.56 (s, 1H, ferrocene), 4.36–
4.39 (br s, 2H, ferrocene), 4.08 (s, 5H, ferrocene), 3.76 (dd,
1H, Hb, Jab = 16.8, Jbx = 10.2 Hz, pyrazoline), 3.67 (dd,
1H, Ha, Jab = 16.8, Jax = 4.2 Hz, pyrazoline);
13C NMR
(CDCl3) d (ppm): 172.1 (C‚S), 158.2 (C‚N), 62.8, (C-5,
pyrazoline), 44.9 (C-4, pyrazoline), 144.7–124.2 (ArAC), 73.8
(ipso-C5H4), 69.8, 69.7 (meta-C5H4), 69.2 68.8, (C5H5), 66.5,
66.0 (ortho-C5H4), ESI-MS m/z: [M
++1] 406.29.
4.2.5. 5-Ferrocenyl-3-(4-bromophenyl)-4,5-dihydropyrazole-1-
carbothioamide (5)
Yield 78%; m.p: 221 C; deep orange solid. Anal. calc. for
C20H18BrFeN3S: C (51.31%) H (3.88%) Br (17.07%) Fe
(11.93%) N (8.97%) S (6.85%); IR mmax (cm
1): 3261, 3173
(NAH), 1578 (C‚N), 1215 (CAN), 1062 (C‚S); 1H NMR
(CDCl3) d (ppm) 7.70 (d, 2H, J= 8.4 Hz, ArAH), 7.64 (d,
2H, J= 8.4 Hz, ArAH), 6.81 (s, 2H, ANH2), 5.91 (dd, 1H,
Hx, Jax = 10.1, Jbx = 10.2 Hz, pyrazoline), 4.63 (s, 1H, fer-
rocene), 4.46 (s, 1H, ferrocene), 4.38 (s, 2H, ferrocene), 4.23
(s, 5H, ferrocene), 3.78 (dd, 1H, Hb, Jab = 16.8,
Jbx = 10.2 Hz, pyrazoline), 3.69, (dd, 1H, Ha, Jab = 16.8,
Jax = 3.0 Hz, pyrazoline);
13C NMR (CDCl3) d (ppm): 173.6
(C‚S), 157.7, (C‚N), 59.6, (C-5, pyrazoline), 42.3 (C-4, pyra-
zoline), 144.5–125.6 (ArAC), 76.3 (ipso-C5H4), 69.9, 69.8
(meta-C5H4), 68.7, 68.3 (C5H5), 67.1, 65.3 (ortho C5H4),
ESI-MS m/z: [M++1] 469.19.
4.2.6. 5-Ferrocenyl-3-(4-nitrophenyl)-4,5-dihydropyrazole-1-
carbothioamide (6)
Yield 69%; m.p: 204 C; deep red solid. Anal. calc. for.
C20H18FeN4O2S: C (55.31%) H (4.18%) Fe (12.86%) N
(12.90%) O (7.37%) S (7.38%); IR mmax (cm
1): 3270, 3182
(NAH), 1581 (C‚N), 1212 (CAN), 1070 (C‚S); 1H NMR
(CDCl3) d (ppm) 7.65 (d, 2H, J= 7.8 Hz, ArAH), 7.32 (d,
2H, J= 7.8 Hz, ArAH), 6.96 (s, 2H, -NH2), 6.01 (dd, 1H,
Hx, Jax = 10.5, Jbx = 11.2 Hz, pyrazoline), 4.67 (s, 1H, fer-
rocene), 4.53 (s, 1H, ferrocene), 4.36 (s, 2H, ferrocene), 4.04
(s, 5H, ferrocene), 3.80 (dd, 1H, Hb, Jab = 16.8,
Jbx = 11.2 Hz, pyrazoline), 3.61, (dd, 1H, Ha, Jab = 16.8,
Jax = 4.8 Hz, pyrazoline);
13C NMR (CDCl3) d (ppm): 177.4
(C‚S), 157.5, (C‚N), 57.52, (C-5, pyrazoline), 44.5 (C-4,Please cite this article in press as: Parveen, H. et al., Synthesis, characterization and bi
lic heterocycles. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arpyrazoline), 144.5–125.7 (ArAC), 75.9 (ipso-C5H4), 69.8, 69.7
(meta-C5H4), 69.1, 69.0 (C5H5), 67.7, 66.4 (ortho C5H4),
ESI-MS m/z: [M++1] 435.29.
4.3. General procedure for the synthesis of 2-(5-ferrocenyl-3-
aryl-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-substituted-
phenyl)thiazoles (7–12)
A mixture of corresponding 5-ferrocenyl-3-substituted aryl-4,
5-dihydro-1H-pyrazol-1-carbothioamide (1–6) (1.03 mmol), 2
-bromo-40-ﬂuoroacetophenone (1.03 mmol) and dichloro-
methane (15 ml) was stirred and reﬂuxed under nitrogen for
5 h. The progress of reaction was monitored by TLC, then
the solvent was removed from the reaction mixture under
reduced pressure. The residue was puriﬁed by column chro-
matography (3:1 Hexane–EtOAc) to afford the pure
compound.
4.3.1. 4-(4-Fluorophenyl)-2-(3,5-diferrocenyl)-4,5-dihydro-1H-
pyrazol-1-yl)thiazole (7)
Yield 52%; m.p: 194 C; brownish solid. Anal. calc. for.
C32H26FFe2N3S: C (62.26%) H(4.57%) F (3.08%) Fe
(18.09%) N (6.81%) S (5.19%); IR mmax cm
1: 3104, 3055,
3022, 2850, 1582, 1471, 1412, 1091, 1045, 885, 842, 825, 722,
690, 485; 1H NMR (CDCl3) d (ppm) 7.96 (d, 2H,
J= 8.4 Hz, Ar0AH) 7.53 (d, 2H, J= 8.4 Hz, Ar0AH), 6.80
(s, 1H, thiazole), 6.25 (dd, 1H, Hx, Jbx = 11.2, Jax = 6.2 Hz,
pyrazoline), 4.68 (s, 2H, ferrocene) 4.67 (s, 2H, ferrocene),
4.65 (s, 2H, ferrocene), 4.61 (s, 2H, ferrocene), 4.26 (s, 5H, fer-
rocene), 4.22 (s, 5H, ferrocene), 3.62 (dd, 1H, Hb, Jab = 17.4,
Jbx = 10.2 Hz, pyrazoline), 3.53 (dd, 1H, Ha, Jab = 17.4,
Jax = 6.3 Hz, pyrazoline);
13C NMR (CDCl3) d (ppm): 171.5
(C-2 thiazole), 165.2 (C-4 thiazole), 146.6–128.6 (2 · ArAC),
122.3 (C-5 thiazole), 72.5, 71.5 (2 · ipso-C5H4). 72.4, 72.1
(2 · meta C5H4), 69.9, 69.8 (2 · C5H5), 64.5, 64.3 (2 · ortho
C5H4); ESI-MS m/z: [M
++1] 616.32.
4.3.2. 4-(4-Fluorophenyl)-2-(5-ferrocenyl-3-phenylethyl)-4,5-
dihydro-1H-pyrazol-1-yl) thiazole (8)
Yield 53%; m.p: 89 C; yellowish brown solid. Anal. calc.
for. C30H26FFeN3S: C (67.29%) H (4.89%) F (3.55%) Fe
(10.43%) N (7.85%) S (5.99%); IR mmax cm
1: 3052, 3024,
2922, 1587, 1470, 1412, 1093, 1046, 885, 842, 826, 722,
691, 487; 1H NMR (CDCl3) d (ppm) 7.96 (d, 2H,
J= 8.4 Hz, Ar0AH), 7.50 (d, 3H, J= 8.4 Hz, Ar0AH),
7.32–7.40 (m, 5H, ArAH), 6.74 (s, 1H, thiazole), 5.28 (dd,
1H, Hx, Jbx = 10.2, Jax = 6.3 Hz, pyrazoline), 4.69 (s, 1H,
ferrocene), 4.65 (s, 1H, ferrocene), 4.62 (s, 2H, ferrocene),
4.25 (s, 5H, ferrocene), 3.90 (dd, 1H, Hb, Jab = 17.4,
Jbx = 10.2 Hz, pyrazoline), 3.54 (dd, 1H, Ha, Jab = 17.4,
Jax = 6.3 Hz, pyrazoline), 3.16–3.19 (m, 2H, CH2), 2.95–
3.01 (m, 2H, CH2);
13C NMR (CDCl3) d (ppm): 171.5 (C-
2 thiazole), 165.2 (C-4 thiazole), 146.6–128.6 (2 · ArAC),
122.3 (C-5 thiazole), 72.5 (ipso-C5H4). 71.3, 71.1 (meta
C5H4), 68.7, 68.6 (C5H5), 65.4, 65.2 (ortho-C5H5); ESI-MS
m/z: [M++1] 536.45.
4.3.3. 4-(4-Fluorophenyl)-2-(5-ferrocenyl-3-phenyl-4,5-
dihydro-1H-pyrazol-1-yl) thiazole (9)
Yield: 59%; m.p: 196 C; deep red solid. Anal. calc. for
C28H22FFeN3S: C (66.28%) H (4.37%) F (3.74%) Feological evaluation of some novel nitrogen and sulphur containing organometal-
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1): 3108, 3055,
2852, 1582, 1484, 1408, 1092, 1045, 884, 840, 820, 726, 693,
488; 1H NMR (CDCl3) d (ppm) 7.97 (d, 2H, J= 7.2 Hz,
Ar0AH), 7.31–7.42 (m, 5H, ArAH), 7.50 (d, 2H, J= 7.2 Hz,
Ar0AH) 6.82 (s, 1H, thiazole), 5.96 (dd, 1H, Hx, Jax = 10.1,
Jbx = 10.2 Hz, pyrazoline),4.72 (s, 1H, ferrocene), 4.64 (s,
1H, ferrocene), 4.59 (s, 2H, ferrocene), 4.24 (s, 5H, ferrocene),
3.76 (dd, 1H, Hb, Jab = 16.8, Jbx = 10.2 Hz, pyrazoline), 3.62
(dd, 1H, Ha, Jab = 16.8, Jax = 6.3 Hz, pyrazoline);
13C NMR
(CDCl3) d (ppm): 164.9 (C-2 thiazole), 159.5 (C-4 thiazole),
145.5–129.2 (ArAC), 126.04 (C-5 thiazole), 78.6 (ipso-C5H4),
73.5, 73.2 (meta-C5H4), 71.1 (C5H5), 68.4, 68.2 (ortho C5H4);
ESI-MS m/z: [M++1] 508.40.
4.3.4. 4-(4-Fluorophenyl)-2-(5-ferrocenyl-3-(4-
hydroxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl) thiazole (10)
Yield 52%; m.p: 215 C; brown solid. Anal. calc. for
C28H22FFeN3OS: C (64.25%) H (4.24%) F (3.63%) Fe
(10.67%) N (8.03%) O (3.06%) S (6.13%); IR mmax (cm
1):
3057, 2855, 1585, 1475, 1405, 1094, 1072, 885, 841, 820, 725,
691, 485; 1H NMR (CDCl3) d (ppm) 7.96 (d, 2H,
J= 8.4 Hz, Ar0AH) 7.70 (d, 2H, J= 8.4 Hz, ArAH), 7.51
(d, 2H, J= 8.4 Hz, Ar0AH) 7.37 (d, 2H, J= 8.4 Hz,
ArAH), 6.80 (s, 1H, thiazole), 5.61 (dd, 1H, Hx, Jbx = 10.2,
Jax = 6.2 Hz, pyrazoline), 4.82 (s, 1H, ferrocene), 4.68 (s,
1H, ferrocene), 4.63 (s, 2H, ferrocene), 4.61 (s, 1H, OH),
4.27 (s, 5H, ferrocene), 3.89 (dd, 1H, Hb, Jab = 17.2,
Jbx = 11.7 Hz, pyrazoline), 3.74 (dd, 1H, Ha, Jab = 17.2,
Jax = 6.2 Hz, pyrazoline);
13C NMR (CDCl3) d (ppm): 171.0
(C-2 thiazole), 162.2 (C-4 thiazole), 145.2–129.5 (ArAC),
128.2 (C-5 thiazole), 78.2 (ipso-C5H4). 71.7, 71.5 (meta
C5H4), 69.8,69.6 (C5H5), 67.4, 67.2 (ortho-C5H5); ESI-MS
m/z: [M++1] 524.40.
4.3.5. 4-(4-Fluorophenyl)-2-(5-ferrocenyl-3-(4-bromophenyl)-
4,5-dihydro-1H-pyrazol-1-yl) thiazole (11)
Yield 52%; m.p: 208 C; yellow solid. Anal. calc. for
C28H21BrFFeN3S: C (57.36%) H (3.61%) Br (13.63%) F
(3.24%) Fe (9.53%) N (7.17%) S (5.47%); IR mmax (cm
1):
3052, 3025, 2921, 2855, 1584, 1475, 1405, 1085, 1045, 1005,
885, 841, 820, 725, 691, 485; 1H NMR (CDCl3) d (ppm) 7.96
(d, 2H, J= 8.4 Hz, Ar0AH) 7.70 (d, 2H, J= 8.4 Hz,
ArAH), 7.62 (d, 2H, J= 8.4 Hz, ArAH) 7.52 (d, 2H,
J= 8.4 Hz, Ar0AH), 6.68 (s, 1H, thiazole), 5.96 (dd, 1H, Hx,
Jbx = 10.2, Jax = 6.3 Hz, pyrazoline), 4.72 (s, 1H, ferrocene),
4.68 (s, 1H, ferrocene), 4.63 (s, 2H, ferrocene), 4.27 (s, 5H, fer-
rocene), 3.87 (dd, 1H, Hb, Jab = 17.4, Jbx = 10.2 Hz, pyrazo-
line), 3.74 (dd, 1H, Ha, Jab = 17.4, Jax = 6.3 Hz, pyrazoline);
13C NMR (CDCl3) d (ppm): 171.2 (C-2 thiazole), 165.0 (C-4
thiazole), 143.2–129.5 (ArAC), 131.1 (C-5 thiazole), 71.0
(ipso-C5H4). 70.7, 70.3 (meta C5H4), 68.7, 68.4 (C5H5), 67.5,
67.2 (ortho-C5H5); ESI-MS m/z: [M
++1] 587.29.
4.3.6. 4-(4-Fluorophenyl)-2-(5-ferrocenyl-3-(4-nitrophenyl)-
4,5-dihydro-1H-pyrazol-1-yl) thiazole (12)
Yield 51%; mp: 179 C; yellow solid. Anal. calc. for.
C28H21FFeN4O2S: C (60.88%) H (3.83%) F (3.44%) Fe
(10.11%) N (10.14%) O (5.79%) S (5.80%); IR mmax (cm
1):
3052, 2922, 2857, 1590, 1477, 1405, 1092, 1074, 886, 841,
822, 728, 692, 486; 1H NMR (CDCl3) d (ppm) 7.97 (d, 2H,
J= 8.4 Hz, Ar0AH) 7.71 (d, 2H, J= 8.4 Hz, ArAH), 7.50Please cite this article in press as: Parveen, H. et al., Synthesis, characterization and bi
lic heterocycles. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.ar(d, 2H, J= 8.4 Hz, Ar0AH) 7.42 (d, 2H, J= 8.4 Hz,
ArAH), 6.79 (s, 1H, thiazole), 5.91 (dd, 1H, Hx, Jax = 16.8,
Jbx = 11.7 Hz, pyrazoline), 4.72 (s, 1H, ferrocene), 4.69 (s,
1H, ferrocene), 4.65 (s, 2H, ferrocene), 4.23 (s, 5H, ferrocene),
3.88 (dd, 1H, Hb, Jab = 17.2, Jbx = 11.7 Hz, pyrazoline), 3.74
(dd, 1H, Ha, Jab = 17.2, Jax = 6.2 Hz, pyrazoline);
13C NMR
(CDCl3) d (ppm): 169.2 (C-2 thiazole), 162.5 (C-4 thiazole),
144.2–129.5 (ArAC), 128.0 (C-5 thiazole), 76.2 (ipso-C5H4).
72.7, 72.4 (meta C5H4), 70.8, 70.2 (C5H5), 68.8, 68.5(ortho-
C5H5); ESI-MS m/z: [M
++1] 553.40.
4.4. In vitro antimicrobial assay
All the newly synthesized compounds (1–6) and (7–12) were
screened for antimicrobial activity against (P. aeruginosa, S.
bovis, E. faecalis, K. pneumonia, E. coli, E. cloacae, MRSA
and S. mutans) and 7 were fungal (C. albicans, C. dublinien-
sis, C. glabrata, C. parapsilosis, C. tropicalis, C. kefyr and
C. krusei) strains by broth microdilution method (Hasan et al.,
2012). Inocula were prepared from an overnight Nutrient
Broth culture plate of the bacterial test strains and Yeast
Peptone Dextrose (YPD) culture plate for fungal test organ-
isms (Himedia Labs, Mumbai, India). Inoculum for the min-
imum inhibitory concentration (MIC) test was prepared by
taking two or three considerably isolated colonies from
respective agar culture plate. These colonies were picked up
by a sterile loop and were transferred into a tube containing
4 to 5 ml of respective sterile liquid medium. This broth was
incubated at 37 C until it attained a desired turbidity (Hasan
et al., 2013).
4.5. Determination of minimum inhibitory concentration
The minimum inhibitory concentration (MIC) was determined
by using a broth microdilution method (Hasan et al., 2012).
Stock standard solutions at 2 mg/mL were prepared in
DMSO for all the compounds to be tested. Working solutions
were prepared by dilution in microtiter plates at concentra-
tions between 500 lg/mL and 0.244 lg/mL using nutrient med-
ium as the diluent. DMSO (50 ll) was used as control and did
not show any inhibitory activity. The bacterial suspension for
each strain was added in the wells of the microtiter plate at the
concentration of 105–106 cfu/mL (colony forming units/mL).
Each inoculum was prepared in its respective medium and
was diluted to 1:100 for the broth microdilution procedure.
The plates were incubated at 37 C with bacterial strains and
at 30 C for fungal stains and the minimum inhibitory concen-
tration (MIC) was recorded after 24 h. Bacterial and fungal
growth was shown by the presence of turbidity in the wells.
The MIC was determined as the lowest concentration of the
compound that completely inhibited the visible bacterial/fun-
gal growth (turbidity) of the organism after 24 h of incubation.
All these determinations represent the mean of three indepen-
dent experiments. The results of antimicrobial activity are
summarized in Table 1 and Table 2.Acknowledgements
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